Loading
A phase 1/2 trial of MK-1045 in acute lymphoblastic leukaemia, run by MSD R&D (China) Co., Ltd., now recruiting.
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) is a phase 1/2 interventional study registered as NCT05579132 by MSD R&D (China) Co., Ltd., with 203 participants planned, started 2022-11-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: MK-1045.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Merck & Co. (MSD) and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Merck & Co. (MSD) and the tag pipeline.
Shares Merck & Co. (MSD) and the tag pipeline.
Shares Merck & Co. (MSD) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/